Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Analysis of Long-term (Investment) Activity Ratios 
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Pfizer Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Net fixed asset turnover 3.40 3.40 3.46 3.26 2.97 2.98 3.14 3.88 4.48 5.46 6.17 6.47 6.64 6.12 5.46 4.79 3.89 3.31 3.01
Total asset turnover 0.31 0.30 0.30 0.28 0.26 0.25 0.26 0.32 0.36 0.48 0.51 0.51 0.52 0.50 0.45 0.39 0.33 0.29 0.27
Equity turnover 0.72 0.69 0.72 0.65 0.64 0.61 0.67 0.71 0.79 0.92 1.05 1.08 1.16 1.12 1.05 0.91 0.79 0.68 0.66

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


The financial ratios indicate notable fluctuations in asset efficiency metrics over the observed periods. The net fixed asset turnover exhibited a rising trend starting from the first available data point in December 2020, reaching a peak of 6.64 by October 2022. Following this peak, there was a steady decline to 2.98 by the end of December 2023, with a slight recovery to about 3.40 projected by mid-2025. This pattern suggests initial improvements in the utilization of fixed assets to generate sales, followed by a period of diminished efficiency, and an expected stabilization in the near future.

The total asset turnover ratio followed a similar pattern, beginning at 0.27 and increasing steadily to a maximum of 0.52 in October 2022. After this peak, it gradually decreased to around 0.25 by December 2023, then showed a gradual improvement to 0.31 by mid-2025. This indicates that the company's overall asset utilization improved over the earlier periods but faced some declining efficiency more recently with expectations of modest recovery.

Equity turnover also presented an increasing trend from 0.66 to its highest point at 1.16 in October 2021. Subsequently, it declined steadily to 0.61 by December 2023 before starting to increase again, reaching approximately 0.72 by mid-2025. This pattern mirrors the other turnover ratios, reflecting enhanced efficiency in generating revenues from shareholder equity in the early periods, followed by a decline, and subsequent stabilization and growth projections.

Overall, the data suggest that the company experienced improvements in asset and equity utilization through late 2021 and 2022, but these enhancements were followed by a period of reduction in efficiency. Projections for 2024 and 2025 indicate a recovery trend across all turnover ratios, implying management's effective response to previous declines or changing operational conditions.

Net Fixed Asset Turnover
Increased significantly from 3.01 to 6.64 between December 2020 and October 2022, then declined to about 3.14 by late 2023, with an expected stabilization around 3.40 by mid-2025.
Total Asset Turnover
Rose from 0.27 to 0.52 by October 2022 before decreasing to 0.25 by the end of 2023; moderate growth anticipated to 0.31 by mid-2025.
Equity Turnover
Jumped from 0.66 to a peak of 1.16 in October 2021, then declined to 0.61 by December 2023 with forecasts showing a rebound to 0.72 by mid-2025.

Net Fixed Asset Turnover

Pfizer Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Revenues 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Property, plant and equipment, net of accumulated depreciation 18,776 18,347 18,393 18,541 18,957 18,803 18,940 17,862 17,488 17,052 16,274 15,441 15,244 15,109 14,882 14,436 14,224 14,011 13,900 14,403 14,113 14,040
Long-term Activity Ratio
Net fixed asset turnover1 3.40 3.40 3.46 3.26 2.97 2.98 3.14 3.88 4.48 5.46 6.17 6.47 6.64 6.12 5.46 4.79 3.89 3.31 3.01
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.04 10.95 10.97 10.80 10.95 10.92 10.89 11.18 11.33 11.51 11.76 11.82 11.57 11.18 11.00 10.75 10.41 9.67 8.73
Amgen Inc. 4.89 4.91 4.89 5.06 4.85 4.70 4.53 4.61 4.58 4.56 4.57 4.73 4.77 4.75 4.69 4.89 4.92 4.93 4.96
Bristol-Myers Squibb Co. 6.47 6.60 6.77 6.87 6.79 6.75 6.77 6.93 7.11 7.30 7.38 7.74 7.90 7.77 7.67 7.75 7.66 7.43 7.22
Danaher Corp. 4.52 4.66 4.78 4.90 5.08 5.20 5.25 6.01 6.68 7.31 7.96 8.40 8.12 7.94 7.77 7.71 7.84 7.59 6.83
Eli Lilly & Co. 2.59 2.65 2.63 2.53 2.62 2.64 2.64 2.70 2.62 2.63 2.81 3.14 3.18 3.22 3.15 3.11 3.02 2.95 2.83
Gilead Sciences Inc. 5.26 5.27 5.28 5.22 5.17 5.13 5.07 4.88 4.91 4.88 4.93 5.01 5.13 5.18 5.27 5.40 5.27 5.06 4.90
Johnson & Johnson 4.13 4.28 4.33 4.28 4.38 4.36 4.28 4.65 4.37 4.58 4.79 5.29 5.21 5.07 4.95 4.95 4.79 4.59 4.40
Merck & Co. Inc. 2.52 2.58 2.70 2.69 2.69 2.66 2.61 2.63 2.62 2.66 2.77 2.89 2.85 2.73 2.53 2.57 2.61 2.55 2.67
Regeneron Pharmaceuticals Inc. 2.94 3.00 3.09 3.12 3.13 3.10 3.16 3.27 3.23 3.19 3.23 3.70 3.91 4.64 4.62 3.99 3.69 2.82 2.64
Thermo Fisher Scientific Inc. 4.48 4.60 4.61 4.50 4.56 4.56 4.54 4.74 4.68 4.68 4.84 5.12 5.02 4.87 4.71 5.54 5.83 5.85 5.45
Vertex Pharmaceuticals Inc. 8.55 8.57 8.98 9.51 8.61 8.68 8.51 8.59 8.47 8.28 8.06 7.78 7.59 7.18 6.92 6.84 6.54 6.51 6.47

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Net fixed asset turnover = (RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024 + RevenuesQ3 2024) ÷ Property, plant and equipment, net of accumulated depreciation
= (14,653 + 13,715 + 17,763 + 17,702) ÷ 18,776 = 3.40

2 Click competitor name to see calculations.


The analyzed financial data reveals several notable trends over the multiple quarterly periods presented.

Revenues (US$ in millions)
Revenues demonstrate a general upward trajectory from early 2020 through the end of 2021, peaking at 24,035 million in October 2021. This period is characterized by steady growth with some fluctuations. However, from 2022 onwards, revenues show increased volatility with notable declines in certain quarters, such as April 2023 and July 2023, when revenues dropped significantly to 18,486 million and 13,007 million respectively. Despite such fluctuations, revenues recover modestly towards the end of 2023 and into early 2024, stabilizing around the 14,000 to 18,000 million range.
Property, Plant and Equipment, Net of Accumulated Depreciation (US$ in millions)
This asset base exhibits a consistent upward trend over the entire period, increasing steadily from 14,040 million in March 2020 to around 18,776 million by June 2025. The growth is gradual and continuous, indicating sustained investment in fixed assets and possibly capacity expansion or modernization. No significant reductions or impairments are evident in the reported periods.
Net Fixed Asset Turnover (ratio)
This efficiency metric shows a distinct pattern: it increases notably from the first available data point in December 2020, reaching a peak ratio of around 6.64 in October 2022. This suggests improving effectiveness in utilizing fixed assets to generate revenues during this timeframe. However, following the peak, the ratio declines steadily through late 2023 and into 2024, stabilizing around a ratio of approximately 3.4 by mid-2025. This downward trend in turnover ratio could indicate diminishing returns on fixed asset investments or slower revenue growth relative to asset expansion.

In summary, the period reflects initial growth in revenues and asset utilization efficiency, supported by steady increases in fixed assets. Later periods show revenue volatility and a decline in asset turnover, pointing to possible challenges in maintaining growth momentum or changes in operational efficiency. The continuous growth in fixed assets suggests ongoing capital investment despite fluctuations in revenue and turnover ratios.


Total Asset Turnover

Pfizer Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Revenues 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Total assets 206,095 208,028 213,396 219,476 216,193 221,095 226,501 215,021 220,168 195,617 197,205 194,350 195,290 183,841 181,476 179,188 169,920 158,818 154,229 178,983 177,934 166,336
Long-term Activity Ratio
Total asset turnover1 0.31 0.30 0.30 0.28 0.26 0.25 0.26 0.32 0.36 0.48 0.51 0.51 0.52 0.50 0.45 0.39 0.33 0.29 0.27
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.43 0.42 0.42 0.39 0.39 0.37 0.40 0.40 0.41 0.42 0.42 0.41 0.40 0.40 0.38 0.37 0.36 0.33 0.30
Amgen Inc. 0.38 0.37 0.35 0.34 0.32 0.30 0.28 0.28 0.28 0.28 0.38 0.38 0.41 0.41 0.40 0.37 0.40 0.38 0.39
Bristol-Myers Squibb Co. 0.50 0.52 0.52 0.51 0.49 0.46 0.47 0.49 0.48 0.49 0.48 0.48 0.47 0.46 0.42 0.41 0.40 0.38 0.36
Danaher Corp. 0.29 0.30 0.31 0.29 0.30 0.28 0.28 0.29 0.33 0.35 0.37 0.39 0.38 0.36 0.35 0.34 0.34 0.33 0.29
Eli Lilly & Co. 0.53 0.55 0.57 0.54 0.54 0.56 0.53 0.55 0.54 0.52 0.58 0.62 0.62 0.62 0.58 0.58 0.56 0.54 0.53
Gilead Sciences Inc. 0.52 0.51 0.48 0.52 0.52 0.48 0.43 0.44 0.44 0.43 0.43 0.43 0.43 0.43 0.40 0.41 0.39 0.37 0.36
Johnson & Johnson 0.47 0.46 0.49 0.49 0.48 0.50 0.51 0.53 0.47 0.47 0.51 0.55 0.54 0.53 0.52 0.51 0.51 0.49 0.47
Merck & Co. Inc. 0.54 0.56 0.55 0.54 0.55 0.58 0.56 0.56 0.56 0.54 0.54 0.55 0.53 0.51 0.46 0.51 0.52 0.51 0.52
Regeneron Pharmaceuticals Inc. 0.37 0.38 0.38 0.37 0.37 0.38 0.40 0.41 0.41 0.41 0.42 0.50 0.52 0.63 0.63 0.57 0.58 0.52 0.50
Thermo Fisher Scientific Inc. 0.43 0.43 0.44 0.42 0.43 0.44 0.43 0.45 0.46 0.46 0.46 0.49 0.47 0.44 0.41 0.53 0.57 0.54 0.47
Vertex Pharmaceuticals Inc. 0.48 0.49 0.49 0.48 0.51 0.43 0.43 0.44 0.47 0.49 0.49 0.52 0.54 0.56 0.56 0.57 0.55 0.53 0.53

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Total asset turnover = (RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024 + RevenuesQ3 2024) ÷ Total assets
= (14,653 + 13,715 + 17,763 + 17,702) ÷ 206,095 = 0.31

2 Click competitor name to see calculations.


The financial data reveals notable fluctuations in revenues and asset metrics over the reported quarters. Revenues demonstrate a strong upward trend between early 2020 and late 2021, rising from approximately $10.1 billion to a peak near $24 billion by the fourth quarter of 2021. This period indicates robust growth. However, this is followed by a partial decline and subsequent volatility from 2022 onwards, with revenues oscillating between roughly $18 billion and $27.7 billion before stabilizing in the $13 billion to $18 billion range through mid-2025.

Total assets exhibit a generally upward trajectory over the analyzed periods. Starting at around $166 billion in early 2020, asset levels gradually increase to approximately $226.5 billion by mid-2023. Beyond this peak, total assets show a mild downturn, declining to roughly $206 billion by mid-2025, suggesting some divestments or depreciation effects might be at play during the latter stages.

The total asset turnover ratio, available from late 2020, shows an initial improvement from 0.27 to a high of approximately 0.52 by mid-2022, indicating enhanced efficiency in utilizing assets to generate revenues during this timeframe. After reaching this peak, the ratio declines gradually, settling around 0.3 by mid-2025. This decrease implies a reduction in asset utilization efficiency in the most recent periods compared to the earlier surge.

Revenues
Strong growth phase from Q1 2020 to Q4 2021, peaking near $24 billion.
Subsequent volatility with decreases and rebounds from 2022 to 2025, stabilizing in the lower range compared to the peak.
Total Assets
Overall upward trend from $166 billion in early 2020 to $226.5 billion by mid-2023.
Moderate decline thereafter down to approximately $206 billion by mid-2025.
Total Asset Turnover
Increase from 0.27 in late 2020 to 0.52 by mid-2022, indicating improved asset efficiency.
Decline afterward to about 0.3 by mid-2025, signifying a decrease in asset utilization efficiency.

In summary, the data reflects a period of accelerated revenue growth and increasing assets culminating around mid-2021 to mid-2023, followed by a phase marked by revenue volatility, a slight contraction in asset base, and reduced asset turnover efficiency. This may suggest changes in market conditions, strategic repositioning, or operational challenges impacting financial performance and asset management in the more recent periods.


Equity Turnover

Pfizer Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Revenues 14,653 13,715 17,763 17,702 13,283 14,879 14,568 13,492 13,007 18,486 24,289 22,638 27,742 25,661 23,838 24,035 18,899 14,516 11,684 10,277 9,864 10,083
Total Pfizer Inc. shareholders’ equity 88,695 90,338 88,203 92,286 87,700 92,282 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424 77,201 75,691 70,042 68,620 63,238 65,259 64,336 65,026
Long-term Activity Ratio
Equity turnover1 0.72 0.69 0.72 0.65 0.64 0.61 0.67 0.71 0.79 0.92 1.05 1.08 1.16 1.12 1.05 0.91 0.79 0.68 0.66
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 40.40 16.94 9.21 8.11 6.79 5.24 4.56 4.35 4.27 3.36 3.62 3.91 3.48 3.65 4.07 4.27 3.66 3.50
Amgen Inc. 4.51 5.28 5.45 4.14 4.99 5.61 4.32 3.35 3.73 4.66 6.77 6.71 10.17 26.68 3.63 2.96 2.93 2.56 2.58
Bristol-Myers Squibb Co. 2.74 2.74 2.96 2.77 2.73 2.76 1.53 1.55 1.41 1.44 1.49 1.43 1.45 1.49 1.29 1.22 1.21 1.14 1.12
Danaher Corp. 0.46 0.47 0.48 0.46 0.47 0.44 0.45 0.49 0.54 0.58 0.63 0.67 0.66 0.65 0.65 0.65 0.62 0.61 0.56
Eli Lilly & Co. 2.91 3.11 3.17 2.87 2.87 2.80 3.17 2.86 2.67 2.47 2.68 2.90 3.40 3.14 3.15 3.58 4.15 3.69 4.35
Gilead Sciences Inc. 1.46 1.49 1.48 1.52 1.51 1.56 1.18 1.22 1.28 1.27 1.27 1.27 1.34 1.37 1.28 1.27 1.34 1.33 1.34
Johnson & Johnson 1.15 1.14 1.24 1.25 1.21 1.22 1.24 1.23 1.20 1.30 1.24 1.29 1.25 1.27 1.27 1.30 1.28 1.28 1.31
Merck & Co. Inc. 1.30 1.32 1.39 1.42 1.43 1.52 1.60 1.44 1.51 1.24 1.29 1.33 1.32 1.32 1.28 1.33 1.41 1.73 1.90
Regeneron Pharmaceuticals Inc. 0.47 0.48 0.48 0.47 0.48 0.49 0.51 0.53 0.53 0.53 0.54 0.64 0.69 0.83 0.86 0.78 0.82 0.77 0.77
Thermo Fisher Scientific Inc. 0.86 0.87 0.86 0.86 0.89 0.93 0.92 0.96 0.99 1.04 1.02 1.01 1.01 1.00 0.96 1.01 1.04 1.02 0.93
Vertex Pharmaceuticals Inc. 0.66 0.67 0.67 0.68 0.70 0.55 0.56 0.58 0.61 0.64 0.64 0.67 0.70 0.73 0.75 0.75 0.73 0.71 0.71

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Equity turnover = (RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024 + RevenuesQ3 2024) ÷ Total Pfizer Inc. shareholders’ equity
= (14,653 + 13,715 + 17,763 + 17,702) ÷ 88,695 = 0.72

2 Click competitor name to see calculations.


The quarterly financial data reveals several notable trends and fluctuations across revenues, shareholders' equity, and equity turnover ratios over the observed periods.

Revenue Trends
Revenues displayed considerable variability throughout the periods under review. Initially, revenues hovered around the 10,000 million US$ mark, ranging from a low of 9,864 million to a high of 11,684 million between March 2020 and December 2020. A substantial increase is observed starting April 2021, with a peak reaching over 24,000 million US$ during October 2021. This peak was followed by some decline and volatility, with revenues falling to approximately 18,486 million in April 2023 and further decreasing to just above 13,000 million in the third quarter of 2023. Modest recovery ensued towards the end of 2023 and the first quarter of 2024, with revenues regaining momentum to nearly 17,700 million in March and June 2025. Despite this rebound, the overall pattern suggests a period of heightened earnings followed by correction and stabilization at a somewhat lower level compared to the peak in late 2021.
Total Shareholders’ Equity
The total shareholders’ equity exhibited a gradual upward trajectory over the examined quarters. Starting from approximately 65,000 million US$ in early 2020, there is consistent growth peaking above 100,000 million in early 2023. Subsequent quarters show some minor fluctuations with equity ranging between roughly 88,000 million and 99,000 million, settling near 88,695 million by mid-2025. The overall upward trend reflects an expansion in the company’s net assets over time, although shorter-term declines suggest possible distributions, buybacks, or valuation adjustments affecting equity levels.
Equity Turnover Ratio
The equity turnover ratio data is provided starting from December 2020 and illustrates fluctuating efficiency in utilizing shareholder equity to generate revenue. The ratio initially rose from 0.66 to a peak of 1.16 in October 2022, indicating improved asset turnover and operational efficiency. After this peak, the ratio generally declined, reaching around 0.61 by December 2024. This decline implies a reduced rate of revenue generation per unit of shareholders' equity in the later periods, which could be tied to changes in revenue dynamics, equity base shifts, or both.
Overall Insights
The combined analysis of these financial indicators suggests a phase of strong revenue growth and asset base expansion followed by a period characterized by more moderate revenue levels and a slight contraction in equity turnover efficiency. The equity base's general increase hints at solid financial foundations, although the decreasing equity turnover ratio toward the end of the data timeline necessitates attention to operational effectiveness and asset utilization. The fluctuations and volatility in revenues, along with the stabilized yet lower equity turnover, may require further qualitative investigation to understand underlying business or market factors influencing these changes.